An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics

BJU International

Volumn 102, Issue 7, 2008, Pages 799-805

  Stephan, Carsten ^a,b   Cammann, Henning ^a,b   Meyer, Hellmuth Alexander ^a,b   Müller, Christian ^a,b   Deger, Serdar ^a,b   Lein, Michael ^a,b   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Biomarkers of Prostate Cancer Group   (France)

Author keywords

Artificial neural network; Prostate biopsy; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER DIAGNOSIS; COMPARATIVE STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; BIOLOGICAL ASSAY; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 50949117677     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07765.x     Document Type: Article

References (36)

1. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002 59 : 2 8
2. Lilja H, Christensson A, Dahlen U et al. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 1991 37 : 1618 25
3. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991 51 : 222 6
4. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998 279 : 1542 7
5. Jung K, Stephan C, Lein M et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996 42 : 1026 33
6. Stephan C, Stroebel G, Heinau M et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4 ng/mL. Cancer 2005 104 : 993 1003
7. Catalona WJ, Partin AW, Finlay JA et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51-4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999 54 : 220 4
8. Jung K, Stephan C, Elgeti U et al. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/L: are they useful tools for early detection and screening of prostate cancer? Int J Cancer 2001 93 : 759 65
9. Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007 43 : 1918 26
10. Mettlin C, Chesley AE, Murphy GP et al. Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate 1999 39 : 153 8
11. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996 48 (Suppl. 55 61
12. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997 79 : 104 9
13. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 1998 52 : 455 61
14. Virtanen A, Gomari M, Kranse R, Stenman UH. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 1999 45 : 987 94
15. Babaian RJ, Fritsche H, Ayala A et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5-4.0 ng/mL. Urology 2000 56 : 1000 6
16. Finne P, Finne R, Auvinen A et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000 56 : 418 22
17. Remzi M, Anagnostou T, Ravery V et al. An artificial neural network to predict the outcome of repeat prostate biopsies. Urology 2003 62 : 456 60
18. Kalra P, Togami J, Bansal BS et al. A neurocomputational model for prostate carcinoma detection. Cancer 2003 98 : 1849 54
19. Snow PB, Smith DS, Catalona WJ. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 1994 152 : 1923 6
20. Stephan C, Cammann H, Semjonow A et al. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002 48 : 1279 87
21. Stephan C, Cammann H, Meyer HA, Lein M, Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett 2007 249 : 18 29
22. Patel D, White PA, Milford Ward A. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. BJU Int 2000 85 : 686 9
23. Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 1996 48 (Suppl. 10 5
24. Yurdakul G, Bangma C, Blijenberg B et al. Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol 2002 42 : 154 8
25. Dittadi R, Franceschini R, Fortunato A et al. Interchangeability and diagnostic accuracy of two assays for total and free prostate-specific antigen: two not always related items. Int J Biol Markers 2007 22 : 154 8
26. Stephan C, Xu C, Cammann H et al. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/mL in 4480 men. World J Urol 2007 25 : 95 103
27. Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006 52 : 59 64
28. Stephan C, Jung K, Soosaipillai A et al. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int 2005 96 : 521 7
29. Stephan C, Xu C, Brown DA et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate 2006 66 : 651 9
30. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004 350 : 2239 46
31. Stephan C, Kramer J, Meyer HA et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007 99 : 1427 31
32. Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6-4.0 ng/mL range. J Urol 2002 168 : 922 5
33. Stephan C, Xu C, Finne P et al. Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. Urology 2007 70 : 596 601
34. Sargent DJ. Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer 2001 91 (Suppl. 1636 42
35. Stephan C, Meyer HA, Kwiatkowski M et al. A (-5, -7) proPSA based artificial neural network to detect prostate cancer. Eur Urol 2006 50 : 1014 20
36. Catalona WJ, Bartsch G, Rittenhouse HG et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2-4 ng/mL prostate specific antigen. J Urol 2004 171 : 2239 44